Member Info for davie_b

That may be true JHFH, but "for basically filling a pullover for years" is still f**king funny.

"for basically filling a pullover for years"

Ha ha ha, I literally LOLed at that one. Nice one Matt :)

Very difficult reading. What a cruel disease. Let’s hope that Hemo will make a real difference.

He won't be able to say this at the AGM will he? Won't this be seen as market-sensitive news?

Very difficult to see how this could be good news in any way. It's free £ for Vlad et al.

Thank you Haywain.

@Haywain: please correct me here as needed.

Some of all of the three patients might have passed, but this is a horrible, aggressive disease. That wouldn't mean that the treatment should be stopped - if there were any concerns at this stage about safety, the FDA wouldn't have signed off on the dosage increase or paediatric trial. The lowest dose might not be life-saving, nor might a higher dose, but the point is that it was safe (as well as the very promising results I'm not going to repeat from the various RNSs).

Agree with Alde here.

However positive we are about Hemo, this SP drop is a proper kick in the **ts. Anybody else expecting this?!

Me too. Added just over a thousand, for better or for worse……………..

Hi everyone. Just in case people are interested, I'm with HL, contacted them and they said they have no flexibility with fees. Don't ask, don't get - right..!

AI suggested that with my total PF value (over £100k) then Interactive Investor was a good choice, onto their 'Plus' plan. I'd appreciate others' thoughts here, if it's not too much off-topic and I write #gohemogo as well :)

I don't think injecting patients is going to affect the SP - the market is expecting this. It's all about the results.

My understanding is that Relapsed/Refractory Acute Myeloid Leukaemia (R/R AML) is, in general, fatal within months. So, in Phase I oncology trials, it is sadly common for patients to pass away from the underlying cancer itself.

The FDA's primary concern in Phase I is whether the therapy harmed the patient (e.g., severe neurotoxicity or Cytokine Release Syndrome). Even if a patient from Cohort 1 ultimately succumbed to their leukaemia after several months, it does not mean the CAR-T therapy failed its safety mandate, nor does it derail the trial.

If we want proof that the safety data in that report is sound, read the RNS from March 31. Hemogenyx announced that they are officially initiating adult dose escalation and opening a pediatric trial. The FDA and the independent Data Safety Monitoring Board (DSMB) are incredibly strict. If the first three patients had experienced severe, fatal toxicities caused by HG-CT-1, the FDA would have slapped a "Clinical Hold" on the trial immediately. They absolutely would not have permitted Hemogenyx to give the drug to children or double the dose in adults.

That sounds very encouraging, will look forward to hearing from Haywain.

They appear to have raised £26.5k.

There's all the money worries gone then... 😂

The wait continues...

I think it's fair enough for people to be a little anxious, until (good) news lands.

Tiny volume, large spread, awaiting news. £10.50 is better than £1.50.

Ah, the classic 470, 463 pattern. That means Vlad’s left knee hurts and we’re expecting an RNS three weeks on Thursday,

Looks like something might be happening.